Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) that is also in single-agent clinical …

• Previous Entry: Animal Bio-Reactors: An Unacceptable Cost to New Z (Scoop.co.nz)
• Next Entry: Extra Solar Panels Coming to U.S.